Equities

Galectin Therapeutics Inc

Galectin Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.34
  • Today's Change-0.03 / -0.89%
  • Shares traded157.73k
  • 1 Year change+98.81%
  • Beta0.7238
Data delayed at least 15 minutes, as of May 03 2024 21:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 02-May-24
Select bar for recommendation details.
Recommendations02-May-24
Buy0
Outperform1
Hold0
Underperform0
Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Galectin Therapeutics Inc share price to rise to 11.00 in the next year from the last price of 3.34.
High229.3%11.00
Med229.3%11.00
Low229.3%11.00

Earnings history & estimates in USD

On Mar 29, 2024, Galectin Therapeutics Inc reported 4th quarter 2023 losses of -0.16 per share. This result was in line with the expectation of the one analyst following the companyand exceeded last year's 4th quarter results by 11.11%.
The next earnings announcement is expected on May 13, 2024.
Average growth rate-2.79%
Galectin Therapeutics Inc reported annual 2023 losses of -0.74 per share on Mar 29, 2024.
Average growth rate-17.70%
More ▼

Revenue history & estimates in USD

Galectin Therapeutics, Inc. did not report revenues for the 4th quarter 2023. However, during the 4th quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Galectin Therapeutics, Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.